MFDeep
An Edge-AI model combining maternal data and fetal biometry to predict fetal macrosomia early and accurately — supporting timely clinical decisions and better outcomes for mothers and babies.
Active clinical development
- Indication
- Fetal macrosomia prediction — women's health
- Data source
- Maternal clinical data, biochemical markers and ultrasound biometry, with on-device real-time inference
- Collaborators
- Genopole, CHSF, France 2030 (public support)
- Partnership availability
- In active development with French clinical partners; open to additional partners
The problem
Gestational diabetes raises the risk of fetal macrosomia — excessive birth weight — which increases complications for both mother and child. Anticipating that risk early enough to act on it is difficult with episodic clinic measurements alone.
The burden is structural and rising. Gestational diabetes prevalence in France reached 16.4% in 2021, more than doubling since 2012 (SNDS / EASD Congress 2024); the weighted European prevalence is 10.9% (meta-analysis across 24 countries), and US prevalence has grown 36% since 2016 (JAMA Internal Medicine, 2025). Globally, fetal macrosomia affects roughly 9% of births — and 15–45% of pregnancies with gestational diabetes (Mayo Clinic). In France alone that translates into ~111,700 gestational-diabetes pregnancies per year.
How MFDeep™ works
MFDeep™ is AI for the prediction of fetal macrosomia, built for pregnant women with established gestational diabetes: an Edge-AI model that combines maternal data and fetal biometry to predict fetal macrosomia early and accurately — supporting timely clinical decisions and better outcomes for mothers and babies.
- GDM status
- Age
- BMI
- Biochemical markers
- Abdominal circumference
- Estimated fetal weight
- Ultrasound biometry
Maternal clinical data
GDM status, age, BMI and other clinical characteristics.
Biochemical markers
Laboratory markers complete the maternal profile.
Ultrasound biometry
Fetal measurements such as abdominal circumference and estimated fetal weight.
Edge-AI model
Trained on diverse real-world data; inference runs on-device.
Macrosomia risk
A clear low-to-high risk prediction, delivered to the medical team in real time.
Clinical impact
- Improved early detection of fetal macrosomia in GDM pregnancies
- Informed decisions on treatment intensification, timing and mode of delivery
- Reduced maternal and neonatal complications
- Better resource allocation and care planning
Key benefits
- Accurate and explainable risk prediction
- Real-time insights at the point of care
- Secure and private on-device processing
- Designed for integration into clinical workflows
- Early prediction from mid-pregnancy to guide management and delivery planning
Current status
A prospective clinical study is active with our French hospital partners. The program launched in partnership with Genopole and CHSF, with support from the France 2030 Innovation Program, and has been awarded a $300K non-dilutive R&D grant via France 2030 with Genopole. It is featured on the French government's digital-health innovation portal, gnius.esante.gouv.fr.
Alongside SweetDeep in diabetes, MFDeep forms the women's-health pillar of NeuTigers' Wearable-AI™ platform portfolio. This status describes the program's development stage; it does not imply regulatory clearance, approval or diagnostic status in any jurisdiction.
Program scope
The current clinical focus is fetal macrosomia risk linked to gestational diabetes. The program's roadmap extends MFDeep toward broader women's health — non-invasive models for menstrual-cycle, fertility and menopause insights. These extensions are in development and carry no validated performance claims at this stage.
On-device inference
Risk prediction runs where care happens.
Privacy preserving
Sensitive maternal data stays local.
Multimodal data fusion
Clinical, biochemical and ultrasound data combined.
Clinically validated platform
Built on NeuTigers' Edge-AI platform.
Global device pathways
Designed for regulatory and commercial scale.
Better insights. Better decisions. Better outcomes.
Supporting healthier pregnancies and brighter futures — with the support of the France 2030 program for innovative AI solutions in women's health.
Collaboration need
We welcome additional maternal-health clinical partners, device partners and payers interested in women's health programs, in France and internationally. Partner with us.
Evidence
- MFDeep featured on gnius.esante.gouv.fr (French government e-health innovation portal)
- MFDeep launch with Genopole and CHSF, supported by France 2030 (2026)
- $300K non-dilutive R&D grant awarded via France 2030 with Genopole
Program status reflects the stage stated above; it does not imply regulatory clearance, diagnostic availability, or commercial deployment unless explicitly stated.